Table 2 PharmGKb clinical annotation levels. Descriptions are adapted from the PharmGKb website available at: https://www.pharmgkb.org/page/clinAnnLevels
PharmGKb Level of Evidence | Description |
|---|---|
1A | Strongest level of evidence. At least one publication and clinical guidelines or a drug label with variant-specific prescribing guidance |
1B | High level of evidence supporting the drug-variant combination, but no variant-specific prescribing recommendations. Supported by at least two independent publications |
2A | Moderate level of evidence. Variants are on the PharmGKb pharmacogene list with implied causality of drug phenotypes. Supported by at least two independent publications |
2B | Moderate level of evidence, possibly conflicting results. Variants are not in known pharmacogenes, but drug-variant associations have been reported in at least two independent publications |
3 | Low level of evidence. Variant-drug association may have been reported in only a single study, several studies may contradict an observed association, or the association is based upon preliminary evidence such as a case report or in vitro molecular studies |
4 | Available evidence score is negative, indicating that the evidence does not support an association between the variant and observed phenotype |